Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minoru Takemoto

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
Aging|May 2, 2023
Renal dysfunction, malignant neoplasms, atherosclerotic cardiovascular diseases, and sarcopenia as key outcomes observed in a three-year follow-up study using the Werner Syndrome RegistryYukari Maeda, Masaya Koshizaka, Mayumi Shoji, et al.
Heliyon|September 9, 2020
Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseasesYoichi Yoshida, Xiao-Meng Zhang, Hao Wang, et al.
Medicine International|July 10, 2024
Serum anti‑KIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseasesTakaki Hiwasa, Yoichi Yoshida, Masaaki Kubota, et al.
International Journal of Molecular Medicine|September 18, 2020
Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertensionShu-Yang Li, Yoichi Yoshida, Eiichi Kobayashi, et al.
Frontiers in Cardiovascular Medicine|February 27, 2023
Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancerShu-Yang Li, Yoichi Yoshida, Masaaki Kubota, et al.
Aging|December 3, 2024
Less frequent skin ulcers among patients with Werner syndrome treated with pioglitazone: findings from the Japanese Werner Syndrome RegistryKazuto Aono, Masaya Koshizaka, Mayumi Shoji, et al.
Diabetes, Obesity & Metabolism|April 18, 2019
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study)Masaya Koshizaka, Ko Ishikawa, Ryoichi Ishibashi, et al.
Journal of Diabetes Investigation|July 6, 2020
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study)Masaya Koshizaka, Ko Ishikawa, Ryoichi Ishibashi, et al.
Scientific Reports|June 30, 2021
Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosisShu-Yang Li, Yoichi Yoshida, Eiichi Kobayashi, et al.
Cancer Science|September 17, 2020
Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseasesMakoto Sumazaki, Hideaki Shimada, Masaaki Ito, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Aging|May 2, 2023
Renal dysfunction, malignant neoplasms, atherosclerotic cardiovascular diseases, and sarcopenia as key outcomes observed in a three-year follow-up study using the Werner Syndrome RegistryYukari Maeda, Masaya Koshizaka, Mayumi Shoji, et al.
Heliyon|September 9, 2020
Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseasesYoichi Yoshida, Xiao-Meng Zhang, Hao Wang, et al.
Medicine International|July 10, 2024
Serum anti‑KIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseasesTakaki Hiwasa, Yoichi Yoshida, Masaaki Kubota, et al.
International Journal of Molecular Medicine|September 18, 2020
Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertensionShu-Yang Li, Yoichi Yoshida, Eiichi Kobayashi, et al.
Frontiers in Cardiovascular Medicine|February 27, 2023
Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancerShu-Yang Li, Yoichi Yoshida, Masaaki Kubota, et al.
Aging|December 3, 2024
Less frequent skin ulcers among patients with Werner syndrome treated with pioglitazone: findings from the Japanese Werner Syndrome RegistryKazuto Aono, Masaya Koshizaka, Mayumi Shoji, et al.
Diabetes, Obesity & Metabolism|April 18, 2019
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study)Masaya Koshizaka, Ko Ishikawa, Ryoichi Ishibashi, et al.
Journal of Diabetes Investigation|July 6, 2020
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study)Masaya Koshizaka, Ko Ishikawa, Ryoichi Ishibashi, et al.
Scientific Reports|June 30, 2021
Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosisShu-Yang Li, Yoichi Yoshida, Eiichi Kobayashi, et al.
Cancer Science|September 17, 2020
Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseasesMakoto Sumazaki, Hideaki Shimada, Masaaki Ito, et al.
Pageof 15